Therapeutics News and Research

RSS

NIH allocated $400 million funding for pain research in 2010

An unprecedented level of federal funding for pain research, some $400 million, was allocated in 2010 by the National Institutes of Health (NIH) through provisions of the American Recovery and Investment Act and the Affordable Care Act to help accelerate advances in pain research, prevention and treatment.

21 May 2011

Edurant receives FDA approval for treatment of HIV-1 infection

The U.S. Food and Drug Administration today approved Edurant (rilpivirine) in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-naive).

21 May 2011

Stony Brook University CFB establishes Biotechnology Commercialization Fund

The Center for Biotechnology (CFB) at Stony Brook University has established the Biotechnology Commercialization Fund to accelerate the development of promising biomedical technologies emerging from Stony Brook University.

21 May 2011

Researchers uncover new details of unusual biological mechanism in brains of diverse species

Researchers at the University of California, San Diego School of Medicine have uncovered new details of an unusual biological mechanism in the brains of diverse species that not only helps regulate how their brains develop, but also how they function later in life. The discovery could lead to new biomarkers for specific neurological diseases in humans and, possibly, the development of drugs to cure them.

21 May 2011

USPTO awards Serina patent for polymer drug delivery technology

Serina Therapeutics, Inc., a pharmaceutical research and development company, announced that the company was awarded a patent from the United States Patent and Trademark Office covering its polymer technology.

21 May 2011

EMA CHMP recommends conditional marketing authorization of FAMPYRA

The Committee for Medicinal Products for Human Use of the European Medicine Agency has recommended conditional marketing authorization of FAMPYRA (prolonged-release fampridine 10 mg tablets) for the improvement of walking in adult patients with multiple sclerosis with walking disability.

20 May 2011

AMT presents long-term efficacy study of Glybera in treatment of lipoprotein lipase deficiency

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today results from a long-term efficacy study of Glybera (alipogene tiparvovec) that showed improved chylomicron metabolism could be used as a biomarker for increased lipoprotein lipase (LPL) activity in those patients missing the gene that produces this protein.

20 May 2011

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present preclinical data demonstrating VB-111's potential synergy and additive therapeutic effect when administered in combination with the conventional chemotherapy cancer treatments.

20 May 2011

Unigene enters Clinical Manufacturing Services Agreement with Cara Therapeutics

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company signed a Clinical Manufacturing Services Agreement with Cara Therapeutics, Inc.

19 May 2011

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, will be presenting data from the NeuVax Phase II adjuvant breast cancer clinical trial at the 2011 annual meeting of The American Society of Clinical Oncology in Chicago.

19 May 2011

Isis receives $5M milestone payment from GSK for initiating ISIS-TTRRx Phase 1 study

Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the initiation of a Phase 1 clinical study for ISIS-TTRRx.

19 May 2011

Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting

Silence Therapeutics plc, a leading global RNA interference therapeutics company, announces that it will present new data from its ongoing Phase I study of Atu027, its lead internal therapeutic candidate, at the 2011 American Society of Clinical Oncology Annual Meeting on 06 June 2011.

19 May 2011

Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting

Nektar Therapeutics today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology being held June 3-7, 2011 in Chicago, Illinois.

19 May 2011

Unigene to present proprietary recombinant production, oral peptide drug delivery technology at TIDES Summit

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company will be presenting a poster and an oral presentation on its propriety recombinant production and oral peptide drug delivery technology during the upcoming 2011 TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Summit being held at the Hynes Convention Center and Sheraton Boston Hotel in Boston, MA from May 22 - 25, 2011.

18 May 2011

NCNPR and Cancer Institute in Jackson partner for anti-cancer drug research

A new partnership to search for cancer-fighting drugs combines compound-identification and screening expertise at the University of Mississippi's National Center for Natural Products Research with the drug development and clinical-trials capabilities at the University of Mississippi Medical Center Cancer Institute.

18 May 2011

Anti-cancer drug discovery partnership formed between UMMC Cancer Institute and Natural Products Center

A new partnership to search for cancer-fighting drugs combines compound-identification and screening expertise at the University of Mississippi’s National Center for Natural Products Research with the drug development and clinical-trials capabilities at the University of Mississippi Medical Center Cancer Institute.

18 May 2011

Excaliber subsidiary merges with VistaGen

Excaliber Enterprises, Ltd. announced today that its wholly-owned subsidiary has merged with VistaGen Therapeutics, Inc., a private biotechnology company focused on stem cell-based drug rescue and drug development. As a result of the Merger, VistaGen is a wholly-owned subsidiary of Excaliber.

17 May 2011

Pernix first quarter net revenues increase 14% to $10.1 million

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company primarily focused on the pediatric market, today announced financial results for the first quarter of 2011.

17 May 2011

Daiichi Sankyo, Regency Therapeutics launch SPRIX Nasal Spray for severe pain

Regency Therapeutics, a newly established division of Luitpold Pharmaceuticals, Inc., and its co-promotion partner Daiichi Sankyo, Inc., announced today that they have launched SPRIX® (ketorolac tromethamine) Nasal Spray and that it is now commercially available.

17 May 2011

Cytori Therapeutics announces independent clinical study results in breast reconstruction presented at the Association of Breast Surgery conference

Cytori Therapeutics, Inc. (NASDAQ: CYTX) reports that surgeons from North Tees and Hartlepool NHS Foundation Trust have presented clinical outcomes using Adipose-Derived Regenerative Cell (ADRC) fat grafting in reconstructive breast surgery at the Association of Breast Surgery Conference in Manchester, UK, May 16-17, 2011. The procedure, referred to by Cytori as RESTORE, was separately investigated in Cytori’s own RESTORE 2 trial.

17 May 2011

Therapeutics News and Research

NIH allocated $400 million funding for pain research in 2010

Edurant receives FDA approval for treatment of HIV-1 infection

Stony Brook University CFB establishes Biotechnology Commercialization Fund

Researchers uncover new details of unusual biological mechanism in brains of diverse species

USPTO awards Serina patent for polymer drug delivery technology

EMA CHMP recommends conditional marketing authorization of FAMPYRA

AMT presents long-term efficacy study of Glybera in treatment of lipoprotein lipase deficiency

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

Unigene enters Clinical Manufacturing Services Agreement with Cara Therapeutics

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

Isis receives $5M milestone payment from GSK for initiating ISIS-TTRRx Phase 1 study

Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting

Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting

Unigene to present proprietary recombinant production, oral peptide drug delivery technology at TIDES Summit

NCNPR and Cancer Institute in Jackson partner for anti-cancer drug research

Anti-cancer drug discovery partnership formed between UMMC Cancer Institute and Natural Products Center

Excaliber subsidiary merges with VistaGen

Pernix first quarter net revenues increase 14% to $10.1 million

Daiichi Sankyo, Regency Therapeutics launch SPRIX Nasal Spray for severe pain

Cytori Therapeutics announces independent clinical study results in breast reconstruction presented at the Association of Breast Surgery conference

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News